Eagle's Eye View: Your Weekly CV Update From ACC.org TAVR in Younger Patients; Atorvastatin vs. Rosuvastatin; Sedentary Behavior and Blood Pressure
7 snips
Nov 6, 2024 Discover the latest on TAVR's surprising outcomes in younger patients with comorbidities. Delve into the showdown between atorvastatin and rosuvastatin, revealing potential advantages for cardiovascular health. Finally, learn about a large trial that looked at how cutting down sedentary time might impact blood pressure in desk workers but found no significant changes. Tune in for intriguing insights from the world of cardiovascular health!
AI Snips
Chapters
Transcript
Episode notes
TAVR in Younger Patients
- TAVR is increasingly used in younger patients, specifically those under 65 with bicuspid valves or significant comorbidities.
- These younger patients often have worse overall health and higher readmission rates compared to older TAVR recipients.
Rosuvastatin vs. Atorvastatin
- Rosuvastatin may offer slightly better cardiovascular mortality benefits compared to atorvastatin.
- However, rosuvastatin might also be associated with a slightly increased risk of type 2 diabetes.
Sedentary Behavior and Blood Pressure
- Replacing an hour of daily sitting with standing or stepping did not significantly lower blood pressure in desk workers.
- This finding challenges the common assumption that standing desks inherently improve blood pressure.